This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2019 Mar 1;21(3):359-360.

doi: 10.1093/europace/euy250.

Idarucizumab in the 'real world': possibilities and limitations

Jan Steffel¹, Hein Heidbüchel²

Affiliations

Affiliations

¹ Department of Cardiology, University Heart Center Zurich, Ramistrasse 100, Zurich, Switzerland.
² Antwerp University and University Hospital, Antwerp, Belgium.

PMID: 30364967
DOI: 10.1093/europace/euy250

Comment

Idarucizumab in the 'real world': possibilities and limitations

Jan Steffel et al. Europace. 2019.

. 2019 Mar 1;21(3):359-360.

doi: 10.1093/europace/euy250.

Authors

Jan Steffel¹, Hein Heidbüchel²

Affiliations

¹ Department of Cardiology, University Heart Center Zurich, Ramistrasse 100, Zurich, Switzerland.
² Antwerp University and University Hospital, Antwerp, Belgium.

PMID: 30364967
DOI: 10.1093/europace/euy250

No abstract available

PubMed Disclaimer

Comment on

Performance of idarucizumab as antidote of dabigatran in daily clinical practice.
van der Wall SJ, van Rein N, van den Bemt B, Kruip MJHA, Meijer K, Te Boome LCJ, Simmers TA, Alings AMW, Tieleman R, Klok FA, Huisman MV, Westerweel PE. van der Wall SJ, et al. Europace. 2019 Mar 1;21(3):414-420. doi: 10.1093/europace/euy220. Europace. 2019. PMID: 30339226

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems